L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study

被引：0

作者：

Duell, J. ^{[1
]}

Gonzalez Barca, E. ^{[2
]}

Liberati, A. M. ^{[3
]}

Salles, G. ^{[4
]}

Gaidano, G. ^{[5
]}

Jurczak, W. ^{[6
]}

Nagy, Z. ^{[7
]}

Papajlk, T. ^{[8
,9
]}

Andre, M. ^{[10
]}

Zinzani, P. L. ^{[11
]}

Kalakonda, N. ^{[12
]}

Ambarkhane, S. ^{[13
]}

Weirather, J. ^{[13
]}

Maddocks, K. ^{[14
]}

Dreyling, M. ^{[15
]}

机构：

[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] IDIBELL, Dept Hematol, Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[3] Azienda Osped Santa Maria, SC Oncoematol, Terni, Italy

[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France

[5] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[6] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[7] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[8] Palacky Univ Olomouc, Olomouc, Czech Republic

[9] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic

[10] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[13] MorphoSys AG, Planegg, Germany

[14] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA

[15] LMU, Univ Hosp, Med Klin & Poliklin 3, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P260

引用

页码：68 / 68

页数：1

共 50 条

[31] Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study
Chen, Guang-Liang
Xue, Kai
Zhang, Qunling
Xia, Zu-guang
Jin, Jia
Li, Ran
Liu, Yizhen
Lv, Fangfang
Hong, Xiaonan
Li, Xiaoqiu
Cao, Junning
CANCER MEDICINE, 2024, 13 (16):
[32] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg
Hawkes, Eliza
Verhoef, Gregor
Haioun, Corinne
Thye, Lim Soon
Heo, Dae Seog
Ardeshna, Kirit
Chong, Geoffrey
Christensen, Jacob Haaber
Shi, Vivian
Lippert, Susanne
Niemeyer, Florian
Piraino, Paolo
Pena, Carol Elaine
Buvaylo, Viktoriya
Childs, Barrett H.
Gorbatchevsky, Igor
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R)
Hernandez-Ilizaliturri, F. J.
Deeb, G.
Zinzani, P. L.
Pileri, S. A.
Malik, F.
Macon, W. R.
Witzig, T. E.
Goy, A.
Czuczman, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[34] Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Korolkiewicz, Roman Pawel
Striebel, Frank
Blum, Kristie
BLOOD, 2015, 126 (23)
[35] Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study
Morschhauser, Franck
Le Gouill, Steven
Feugier, Pierre
Bailly, Sarah
Nicolas-Virelizier, Emmanuelle
Bijou, Fontanet
Salles, Gilles A.
Tilly, Herve
Fruchart, Christophe
Van Eygen, Koen
Snauwaert, Sylvia
Bonnet, Christophe
Haioun, Corinne
Thieblemont, Catherine
Bouabdallah, Reda
Wu, Ka Lung
Canioni, Danielle
Meignin, Veronique
Cartron, Guillaume
Houot, Roch
LANCET HAEMATOLOGY, 2019, 6 (08): : E429 - E437
[36] Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Gaidano, Gianluca
Gonzales-Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Kuffer, Christian
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
REVISTA CHILENA DE LITERATURA, 2024, (109):
[37] Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Melani, Christopher
Lakhotia, Rahul
Pittaluga, Stefania
Phelan, James D.
Huang, Da Wei
Wright, George
Simard, Jillian
Muppidi, Jagan R.
Thomas, Craig J.
Ceribelli, Michele
Tosto, Frances A.
Yang, Yandan
Xu, Weihong
Davies-Hill, Theresa
Pack, Svetlana
Peer, Cody J.
Arisa, Oluwatobi
Mena, Esther
Lindenberg, Maria L.
Bergvall, Ethan
Portell, Craig A.
Farah, Rafic J.
Lee, Seung Tae
Pradhan, Amynah
Morrison, Candis
Tadese, Atekelt
Juanitez, Anna M.
Lu, Crystal
Jacob, Allison P.
Simmons, Heidi
Figg, William D.
Steinberg, Seth M.
Jaffe, Elaine S.
Roschewski, Mark
Staudt, Louis M.
Wilson, Wyndham H.
BLOOD, 2023, 142
[38] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
Van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Marie Jose
Schuster, Stephen J.
Salles, Gilles Andre
Maziarz, Richard Thomas
Anak, Oezlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
BLOOD, 2017, 130
[39] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Maakaron, Joseph
Asch, Adam S.
Popplewell, Leslie L.
Collins, Graham P.
Flinn, Ian W.
Ghosh, Nilanjan
Keane, Colin
Ku, Matthew
Mehta, Amitkumar
Roschewski, Mark
O'Hear, Carol
Ren, Xuehan
Villa, Bertha
Lal, Indu
Smith, Sonali M.
Advani, Ranjana H.
BLOOD, 2022, 140 : 3728 - 3730
[40] Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Gaidano, Gianluca
Gonzales-Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Kuffer, Christian
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
HAEMATOLOGICA, 2024, 109 (02) : 553 - 566

← 1 2 3 4 5 →